<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045079</url>
  </required_header>
  <id_info>
    <org_study_id>21-000537</org_study_id>
    <nct_id>NCT05045079</nct_id>
  </id_info>
  <brief_title>Rhythm Control and Potential Early Surgery for Tricuspid Regurgitation</brief_title>
  <official_title>Tricuspid Regurgitation Due to Atrial Fibrillation - Impact of Rhythm Control and Early Surgery (TR-ES Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand the clinical impact of non-surgical and surgical&#xD;
      treatment in atrial fibrillation induced tricuspid regurgitation (AFTR).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in KCCQ QOL scores</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>The KC Cardiomyopathy Questionnaire (0-100 scale) assess subject perception of heart failure limitation on their life; scale of extremely limited, quite a bit limited, moderately limited, slightly limited, not at all limited, limited for other reasons or did not do the activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in right ventricular (RV) end-diastolic volume</measure>
    <time_frame>Baseline, 6 months</time_frame>
    <description>Assessed by repeat cardiac MRI RV end diastolic volume reported in mL/m2</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Severe Tricuspid Valve Regurgitation (Disorder)</condition>
  <arm_group>
    <arm_group_label>Severe tricuspid regurgitation due to atrial fibrillation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Subjects will receive standard of care procedure right heart catheterization with a inferior vena caval (IVC) occlusion maneuver.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Inferior Vena Caval (IVC) Occlusion maneuver</intervention_name>
    <description>During standard of care right heart catheterization (RHC), a second catheter will be inserted next to the catheter that was placed for the RHC in the jugular vein or femoral vein to assess the degree of pericardial restraint from the severe tricuspid regurgitation that may increase left sided filling pressures.</description>
    <arm_group_label>Severe tricuspid regurgitation due to atrial fibrillation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years.&#xD;
&#xD;
          -  Moderate-severe or severe TR while in atrial fibrillation.&#xD;
&#xD;
          -  Ambulatory (not wheelchair/scooter dependent).&#xD;
&#xD;
          -  Patient willing to consider surgical management of severe TR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Systolic pulmonary artery pressure&gt;70 mmHg with a fixed pulmonary vascular resistance&#xD;
             &gt;7 Wood units by catheterization.&#xD;
&#xD;
          -  Ejection fraction &lt;40%.&#xD;
&#xD;
          -  Obstructive hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  Constrictive pericarditis or tamponade.&#xD;
&#xD;
          -  Active myocarditis.&#xD;
&#xD;
          -  Complex congenital heart disease.&#xD;
&#xD;
          -  Other valve disease requiring surgical intervention.&#xD;
&#xD;
          -  Terminal illness (other than HF) with expected survival of less than 1 year.&#xD;
&#xD;
          -  Enrollment or planned enrollment in another therapeutic clinical trial in next 3&#xD;
             months.&#xD;
&#xD;
          -  Inability to comply with planned study procedures.&#xD;
&#xD;
          -  Pregnancy or breastfeeding mothers.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yogesh Reddy, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Colleen Irlbeck</last_name>
    <phone>507-266-6879</phone>
    <email>Irlbeck.Colleen@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Yogesh N. V. Reddy, M.B.B.S.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

